Doxazosin Gastrointestinal Therapeutic System (Gits) in Benign Prostatic Hyperplasia (Bph)

Gratzke, Peter

doi:10.1097/00005392-199904020-00444

Search citation statements

Order By: Relevance

Paper Sections

Select...

Mechanisms Underlying the Adverse Events Of α‐Blockers1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2000

2002

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a slow‐release formulation of doxazosin (‘gastrointestinal therapeutic system’) is as effective in reducing blood pressure and LUTS ( Fig. 1) as is the standard formulation, but has an improved tolerability; the respective adverse event incidences were 56% and 44% [46,47]. Finally, alfuzosin produced greater blood pressure reductions than did tamsulosin in a direct comparative study [48] ( Fig.…”

Section: Mechanisms Underlying the Adverse Events Of α‐Blockersmentioning

confidence: 99%

α‐Blockers and lower urinary tract function: more than smooth muscle relaxation?

Michel¹,

Schäfers²,

Goepel³

2000

BJU International

View full text Add to dashboard Cite

Section: Mechanisms Underlying the Adverse Events Of α‐Blockersmentioning

confidence: 99%

α‐Blockers and lower urinary tract function: more than smooth muscle relaxation?

Michel¹,

Schäfers²,

Goepel³

2000

BJU International

View full text Add to dashboard Cite

α-Adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with α-adrenoceptor antagonists

Andersson

2002

World J Urol

View full text Add to dashboard Cite

The selective blockade of alpha1-adrenoceptors (ARs) is now a well-accepted and widely used treatment for patients presenting with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and bladder outlet obstruction. The sites of action of the currently used alpha1-AR antagonists when relieving LUTS have not yet been established, but it seems clear that effects on prostatic as well as non-prostatic tissues are important. Alpha1-ARs in the bladder, urethra, and vas deferens, on ganglia and nerve terminals, and in the central nervous system (CNS) may all influence LUTS and the clinical effects of alpha1-AR antagonists. The relevance of alpha1-AR subtype selectivity for the clinical usefulness of existing drug therapy has still not been clarified, but it cannot be dismissed that blockading both alpha1A- and alpha1D-ARs is necessary for optimal clinical effect. Despite the above uncertainties, there seems to be a consensus that clinically available alpha1-AR antagonists provide a safe, effective and generally well-tolerated therapy for patients with LUTS.

show abstract

Terazosin, doxazosin, and prazosin: current clinical experience

Akduman

Crawford

2001

Urology

View full text Add to dashboard Cite

Doxazosin Gastrointestinal Therapeutic System (Gits) in Benign Prostatic Hyperplasia (Bph)

Cited by 3 publications

References 0 publications

α‐Blockers and lower urinary tract function: more than smooth muscle relaxation?

α‐Blockers and lower urinary tract function: more than smooth muscle relaxation?

α-Adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with α-adrenoceptor antagonists

Terazosin, doxazosin, and prazosin: current clinical experience

Contact Info

Product

Resources

About